“Chiltern has experienced a healthy number of requests from our clients in this region, and forming a legal entity is a natural progression to our work there,” said Armand Czaplinski, Chiltern’s executive director of global country management, who will be leading the effort in Israel.
“Israel is an attractive location to conduct clinical trials as it has many key opinion leaders (KOL) in clinical research and outstanding quality of research,” he said. “Israel has some of the most skilled and educated work forces with the highest number of doctors, scientists and engineers per capita than any other country. Another key advantage is that the majority of Israel’s population belongs to the same health maintenance organization and this facilitates a quick start for clinical trials and reduces the overall project timelines.”
Glenn Kerkhof, Chiltern CEO, said, “We are delighted to add Israel to our established global footprint to better serve our clients. It is essential for Chiltern to have operations in Israel to tap into the renowned clinical research expertise, experienced investigators and key opinion leaders available in this country.”
